Developer docs
API playgroundTry for free, no card

Search company profiles

EBR Systems

Full company profile

uuid0000btt

Namestring
EBR Systems
Legal namestring
EBR Systems, Inc.
Company typeenum
Public
Founded yearint
2003
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac resynchronization therapy, wireless cardiac pacing, leadless pacing electrode, heart failure medical devices, left ventricular endocardial pacing
Industry2 codes
PRIMARYHLAHAFAC
Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Resynchronization Therapy Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1WiSE CRT System Device Sales
TypeHardware Sales
Description

EBR Systems generates revenue from the sale of its WiSE CRT System hardware, including the electrode, transmitter, battery, coupler, programmer, and delivery sheath. The company reported initial commercial revenue of $1.6 million in 2025 following FDA approval and U.S. commercial launch. The target average selling price (ASP) for the system is US$45,000.

tradingview.com
2CMS Reimbursement (NTAP and TPT)
TypeHardware Sales
Description

CMS provides New Technology Add-On Payment (NTAP) of up to $41,145 per procedure for inpatient use, on top of base DRG reimbursement. Transitional Pass-Through (TPT) reimbursement supports outpatient settings, both effective October 1, 2025. Additionally, CMS has initiated a National Coverage Determination (NCD) for the WiSE wireless LV pacing system, with a projected decision in early 2027. EBR is also the first technology to enter CMS' Transitional Coverage for Emerging Technologies (TCET) pathway.

ebrsystemsinc.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details3 tiers
1WiSE CRT System target average selling price (ASP)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

EBR has upgraded its WiSE CRT System target ASP from US$35,000 to US$45,000. The system consists of multiple components: electrode, battery, transmitter, programmer, delivery sheath, and coupler.

ebrsystemsinc.com
2CMS NTAP (New Technology Add-On Payment) for inpatients
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

CMS provides up to $41,145 in additional payment per procedure on top of the base DRG payment for Medicare inpatients. Effective October 1, 2025.

ebrsystemsinc.com
3CMS TPT (Transitional Pass-Through) for outpatients
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

CMS provides HCPCS code for TPT reimbursement for outpatient settings, effective October 1, 2025. Combined with NTAP, these reimbursement programs support hospital adoption.

ebrsystemsinc.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EBR Systems develops, manufactures, and commercializes the WiSE (Wireless Stimulation Endocardially) System, the first FDA-approved wireless cardiac pacing system for heart failure patients. The system delivers leadless left ventricular endocardial pacing (LVEP) for cardiac resynchronization therapy (CRT) through a rice-grain-sized electrode powered by subcutaneous ultrasound, sold to hospitals and electrophysiologists at a target average selling price of US$45,000 per system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 16.4% improvement in left ventricular end systolic volume (LVESV) in heart failure patients in the first 6 months post-implant
+7 more records
Product overview1 text field

EBR Systems offers the WiSE System, a single unified product platform for wireless cardiac resynchronization therapy. The system consists of the WiSE Electrode (a leadless left ventricular endocardial pacing device), Battery Module, Transmitter, Programmer, Delivery Sheath, and Coupler components that work together to deliver leadless biventricular pacing for heart failure patients. The WiSE System is the world's only FDA-approved wireless cardiac pacing device, using proprietary ultrasound technology to pace the left ventricle without requiring transvenous leads. The system is designed to work with patients' existing co-implanted pacemakers, ICDs, or CRT devices to provide synchronized cardiac resynchronization therapy.

Product and service1 record
1WiSE System (Wireless Stimulation Endocardially)
CategoryCardiac Resynchronization Therapy Devices
Description

The WiSE System is the world's only FDA-approved wireless cardiac pacing device for heart failure, delivering leadless left ventricular endocardial pacing (LVEP) for cardiac resynchronization therapy. It uses proprietary ultrasound technology to pace the left ventricle without transvenous leads.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Major US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. HCA Healthcare is one of the largest hospital operators in the US, with significant cardiac care capabilities.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Major US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. Advocate Health is one of the largest healthcare systems in the US.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Major US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. CHRISTUS Health operates hospitals and healthcare services across the US and Latin America.

4Telectronics Legacy Connection
Strategic tierMinorTypeOthersAnnounced on2017-01-01
Description

Trevor Moody, a former Telectronics biomedical engineer, connected EBR to Australian investors. Telectronics was Australia's first successful high-tech medical electronics company (founded in Sydney in 1963), manufacturing pacemakers and implantable defibrillators. This connection explains EBR's ASX listing and Australian investor base, as Telectronics pioneered pacemaker technology in Australia.

ebrsystemsinc.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in cardiac rhythm management including conventional CRT-D systems and the Micra leadless pacemaker. Competes indirectly with WiSE in serving heart failure patients but dominates the broader CRT market that EBR's WiSE system augments rather than displaces.

2Abbott
TypeBroad incumbent
Description

Major manufacturer of conventional CRT systems and leadless pacemakers (Nanostim lineage). Competes in the same cardiac rhythm management space and represents both a co-implant compatibility partner and a potential future competitor in leadless LVEP.

TypeBroad incumbent
Description

Major incumbent in cardiac rhythm management with conventional CRT systems and a growing leadless pacemaker portfolio. Competes in the same hospital accounts and EP physician relationships that EBR is now selling into.

TypeDirect peer
Description

Developer of the Barostim implantable neuromodulation system for heart failure patients — a competing implantable device approach for the same advanced heart failure population EBR targets with WiSE, making it the most analogous direct peer in terms of patient indication and use setting.

TypeDirect peer
Description

European-based cardiac rhythm management company with CRT and leadless pacemaker products. Closest direct comparable as a smaller, technology-focused CRT specialist competing in the same electrophysiology hospital accounts.

TypeEmerging player
Description

Cardiac device company with heart failure and cardiac rhythm management products. Competes in adjacent cardiac device categories and shares the same specialty hospital accounts targeted by EBR.

TypeEmerging player
Description

Implantable neuromodulation company (sacral and now tibial stimulation) that shares the miniaturized implantable technology paradigm with EBR's WiSE electrode. Both pursue leadless or minimally-invasive implantable approaches with rechargeable/ultrasound energy concepts.

8Acutus Medical
TypeEmerging player
Description

Cardiac electrophysiology mapping and ablation company with similar small-cap medtech profile to EBR. Operates in the same EP lab and electrophysiologist customer base that EBR's WiSE System depends on for adoption.

9MicroPort Scientific
TypeRegional player
Description

China-based medical device company with a cardiac rhythm management business including CRT products. Comparable technology category but primarily serves the Asia-Pacific market where EBR has limited presence outside Australia.

TypeOthers
Description

Implantable neuromodulation company chaired by Allan Will (EBR's Executive Chairman). Shares a leadership connection and pursues a similar minimally-invasive implantable device paradigm, making it a thematically related peer rather than a direct competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EBR Systems

Cardiac Resynchronization Therapy Devicesebrsystemsinc.com

EBR Systems firmographics

Firmographics
Name
EBR Systems
Legal name
EBR Systems, Inc.
Website
https://ebrsystemsinc.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

EBR Systems industry classification

Industry
Product category
Cardiac Resynchronization Therapy Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAC
Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac resynchronization therapy
  • Wireless cardiac pacing
  • Leadless pacing electrode
  • Heart failure medical devices
  • Left ventricular endocardial pacing

Where EBR Systems is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

EBR Systems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. WiSE CRT System Device Sales: EBR Systems generates revenue from the sale of its WiSE CRT System hardware, including the electrode, transmitter, battery, coupler, programmer, and delivery sheath. The company reported initial commercial revenue of $1.6 million in 2025 following FDA approval and U.S. commercial launch. The target average selling price (ASP) for the system is US$45,000.
  2. CMS Reimbursement (NTAP and TPT): CMS provides New Technology Add-On Payment (NTAP) of up to $41,145 per procedure for inpatient use, on top of base DRG reimbursement. Transitional Pass-Through (TPT) reimbursement supports outpatient settings, both effective October 1, 2025. Additionally, CMS has initiated a National Coverage Determination (NCD) for the WiSE wireless LV pacing system, with a projected decision in early 2027. EBR is also the first technology to enter CMS' Transitional Coverage for Emerging Technologies (TCET) pathway.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goWiSE CRT System target average selling price (ASP)
Transaction based/ take ratePay-as-you-goCMS NTAP (New Technology Add-On Payment) for inpatients
Transaction based/ take ratePay-as-you-goCMS TPT (Transitional Pass-Through) for outpatients

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

EBR Systems product offering

Product offering

Core offering

EBR Systems develops, manufactures, and commercializes the WiSE (Wireless Stimulation Endocardially) System, the first FDA-approved wireless cardiac pacing system for heart failure patients. The system delivers leadless left ventricular endocardial pacing (LVEP) for cardiac resynchronization therapy (CRT) through a rice-grain-sized electrode powered by subcutaneous ultrasound, sold to hospitals and electrophysiologists at a target average selling price of US$45,000 per system.

Product overview

EBR Systems offers the WiSE System, a single unified product platform for wireless cardiac resynchronization therapy. The system consists of the WiSE Electrode (a leadless left ventricular endocardial pacing device), Battery Module, Transmitter, Programmer, Delivery Sheath, and Coupler components that work together to deliver leadless biventricular pacing for heart failure patients. The WiSE System is the world's only FDA-approved wireless cardiac pacing device, using proprietary ultrasound technology to pace the left ventricle without requiring transvenous leads. The system is designed to work with patients' existing co-implanted pacemakers, ICDs, or CRT devices to provide synchronized cardiac resynchronization therapy.

Differentiator

Problem solved

Functional benefit

Products and services

  • WiSE System (Wireless Stimulation Endocardially) The WiSE System is the world's only FDA-approved wireless cardiac pacing device for heart failure, delivering leadless left ventricular endocardial pacing (LVEP) for cardiac resynchronization therapy. It uses proprietary ultrasound technology to pace the left ventricle without transvenous leads.

Quantifiable outcome

  • 16.4% improvement in left ventricular end systolic volume (LVESV) in heart failure patients in the first 6 months post-implant
  • +7 more outcomes

Companies that use EBR Systems

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

EBR Systems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EBR Systems partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and minor.

  • HCA HealthcaremajorChannel Partner/ Reseller/ Distributor · 1 January 2026Major US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. HCA Healthcare is one of the largest hospital operators in the US, with significant cardiac care capabilities.
  • Advocate HealthmajorChannel Partner/ Reseller/ Distributor · 1 January 2026Major US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. Advocate Health is one of the largest healthcare systems in the US.
  • CHRISTUS HealthmajorChannel Partner/ Reseller/ Distributor · 1 January 2026Major US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. CHRISTUS Health operates hospitals and healthcare services across the US and Latin America.
  • Telectronics Legacy ConnectionminorOthers · 1 January 2017Trevor Moody, a former Telectronics biomedical engineer, connected EBR to Australian investors. Telectronics was Australia's first successful high-tech medical electronics company (founded in Sydney in 1963), manufacturing pacemakers and implantable defibrillators. This connection explains EBR's ASX listing and Australian investor base, as Telectronics pioneered pacemaker technology in Australia.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

EBR Systems competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Global leader in cardiac rhythm management including conventional CRT-D systems and the Micra leadless pacemaker. Competes indirectly with WiSE in serving heart failure patients but dominates the broader CRT market that EBR's WiSE system augments rather than displaces.
  • Abbott: Major manufacturer of conventional CRT systems and leadless pacemakers (Nanostim lineage). Competes in the same cardiac rhythm management space and represents both a co-implant compatibility partner and a potential future competitor in leadless LVEP.
  • Boston Scientific: Major incumbent in cardiac rhythm management with conventional CRT systems and a growing leadless pacemaker portfolio. Competes in the same hospital accounts and EP physician relationships that EBR is now selling into.

Direct peers

  • CVRx: Developer of the Barostim implantable neuromodulation system for heart failure patients — a competing implantable device approach for the same advanced heart failure population EBR targets with WiSE, making it the most analogous direct peer in terms of patient indication and use setting.
  • Biotronik: European-based cardiac rhythm management company with CRT and leadless pacemaker products. Closest direct comparable as a smaller, technology-focused CRT specialist competing in the same electrophysiology hospital accounts.

Emerging players

  • LivaNova: Cardiac device company with heart failure and cardiac rhythm management products. Competes in adjacent cardiac device categories and shares the same specialty hospital accounts targeted by EBR.
  • Axonics: Implantable neuromodulation company (sacral and now tibial stimulation) that shares the miniaturized implantable technology paradigm with EBR's WiSE electrode. Both pursue leadless or minimally-invasive implantable approaches with rechargeable/ultrasound energy concepts.
  • Acutus Medical: Cardiac electrophysiology mapping and ablation company with similar small-cap medtech profile to EBR. Operates in the same EP lab and electrophysiologist customer base that EBR's WiSE System depends on for adoption.

Regional players

  • MicroPort Scientific: China-based medical device company with a cardiac rhythm management business including CRT products. Comparable technology category but primarily serves the Asia-Pacific market where EBR has limited presence outside Australia.

Others

  • SetPoint Medical: Implantable neuromodulation company chaired by Allan Will (EBR's Executive Chairman). Shares a leadership connection and pursues a similar minimally-invasive implantable device paradigm, making it a thematically related peer rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EBR Systems social profiles

Digital presence

EBR Systems compliance and trust

Trust signal

Compliance1 record

EBR Systems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EBR Systems leadership team

Management profile

Number of profiles

Profiles16 records

EBR Systems funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EBR Systems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EBR Systems

What does EBR Systems do?

EBR Systems develops, manufactures, and commercializes the WiSE (Wireless Stimulation Endocardially) System, the first FDA-approved wireless cardiac pacing system for heart failure patients. The system delivers leadless left ventricular endocardial pacing (LVEP) for cardiac resynchronization therapy (CRT) through a rice-grain-sized electrode powered by subcutaneous ultrasound, sold to hospitals and electrophysiologists at a target average selling price of US$45,000 per system.

Is EBR Systems a public or private company?

EBR Systems is a public company. It is classified as public and is currently operating.

When was EBR Systems founded?

EBR Systems was founded in 2003. It employs 101 to 250 people.

Where is EBR Systems based?

EBR Systems is headquartered in Sunnyvale, United States, in the North America region.

How does EBR Systems make money?

Two revenue lines are on record. WiSE CRT System Device Sales are the primary driver. The others are CMS Reimbursement (NTAP and TPT).

Who are EBR Systems's main competitors?

Broad incumbents on record are Medtronic, Abbott and Boston Scientific. Direct peers are CVRx and Biotronik. Emerging players are LivaNova, Axonics and Acutus Medical. MicroPort Scientific is listed as a regional player. SetPoint Medical is listed as an others.

Does EBR Systems have an API?

No public API is recorded for EBR Systems.

What industry is EBR Systems in?

EBR Systems's product category is Cardiac Resynchronization Therapy Devices. Its primary akta.pro industry code is HLAHAFAC, Cardiac Rhythm Management (Pacemakers, ICDs, CRT), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEBR Systems at Bell Potter Healthcare Conference: focus shifts to deeper useEBR Systems outlined its WiSE wireless pacing business at the Bell Potter Healthcare Conference, reporting 157 implants across 40 hospitals and 100 trained electrophysiologists. Q3 2024 implants fell to 40, and the company now focuses on deeper use in existing accounts, targeting one implant per month per trained physician. A pending Medicare National Coverage Determination could double the addressable patient base.EIN PresswireEBR moves to make WiSE cardiac pacing available in Australia | StockheadEBR Systems applied to Australia's TGA for inclusion of its WiSE cardiac pacing system on the ARTG, following FDA approval. The priority review pathway, granted in April, is expected to reduce the evaluation period. The submission supports EBR's plan to expand beyond the US market.FinancialContent Business PageEBR Systems Appoints Robert Canby, MD, as Chief Medical OfficerEBR Systems appointed Robert Canby, MD, as Chief Medical Officer, succeeding Spencer Kubo. Canby, a board-certified electrophysiologist, will lead clinical strategy and physician education for the WiSE System. He will continue his clinical role at St. David's Medical Center.Investing.comEarnings call transcript: EBR’s Q3 2026 revenue miss sparks sharp selloffEBR reported Q3 revenue of $3.5 million, missing the $4.7 million forecast by 25.53%, and completed 40 WiSE procedures. The miss triggered a 40.43% pre-market stock drop, and management said it intentionally slowed commercial activity to focus on deeper account penetration. The company expects a PMA supplement for echo-induced arrhythmias and a CMS coverage decision in December.Investing.comEarnings call transcript: EBR’s Q3 2026 revenue miss sparks sharp selloffEBR reported Q3 revenue of $3.5 million, missing the $4.7 million forecast by 25.53%, and completed 40 WiSE procedures. The miss triggered a 40.43% pre-market stock drop, and management said it intentionally slowed commercial activity to focus on deeper account penetration. No formal guidance was given, but the company expects a PMA supplement and a new manufacturing facility.AInvestEBR Systems - Continues cybersecurity remediation and hardening activitiesEBR Systems, a medical technology firm, continues cybersecurity remediation after a February 2026 breach that exposed PHI including patient names and medical record numbers. The company did not disclose the number of affected individuals or the attack's nature, and said the breach did not materially disrupt operations. It holds cyber insurance to cover incident-related costs.KalkineEBR Systems (ASX:EBR) WiSE Implant Milestone Strengthens Growth Outlook While Funding Risks RemainEBR Systems reported 117 cumulative WiSE CRT System implants after FDA approval, with 46 completed in the June 2026 quarter. The company trained 90 physicians across 30 hospital sites, and CMS selected WiSE for its Transitional Coverage for Emerging Technologies pathway. EBR remains unprofitable with a half-year net loss of about US$34.5 million.AInvestThe 92 Million CDIs Nobody Asked For — What EBR Systems' Director-Linked Placement Actually MeansEBR Systems applied to the ASX on August 25 to list 92 million CHESS Depository Interests, a director-linked tranche of an A$150 million raise announced in June, after shareholder approval on August 18. The 92 million CDIs, at A$0.38 each, represent roughly 24% of the raise and add to a float of over 700 million CDIs. The company lost US$48.8 million in fiscal 2025 and holds about US$87 million in cash.KalkineEBR Systems (ASX:EBR) Balances WiSE Commercial Growth Against Funding RiskEBR Systems raised AUD 150 million in June 2026 at a 19.1% discount to prior close, but its H1 2026 net sales were USD 5 million on 87 implants, with a Q2 net loss of USD 17.5 million. The company faces a going-concern doubt and a pending shareholder vote on a final AUD 35 million tranche.KalkineEBR Systems Surpasses 100th WiSE Implant, Completes Capital Raise Tranches and Secures Major Purchasing AgreementsEBR Systems surpassed its 100th commercial WiSE implant in Q2 2026, with total implants reaching 117. The company completed the first two tranches of an A$150 million capital raise and secured purchasing agreements with HCA Healthcare, Advocate Health, and CHRISTUS Health. The final A$35 million tranche is expected to close by 24 August 2026.